Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Auditor change
BIOENVISION INC (BIVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2007 8-K Quarterly results
10/10/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "Bioenvision and Genzyme File Petition in Delaware Court Petition Seeks Special Meeting to be Reconvened in late October to Reopen Polls"
09/12/2007 8-K Quarterly results
Docs: "Bioenvision Reports Financial Results for Fourth Quarter and Year End 2007 - Conference Call to be Held Today at 10:00 a.m. -"
08/31/2007 8-K Other Events
08/16/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "BIOENVISION PROVIDES EVOLTRA® REGULATORY UPDATE"
07/30/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/27/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "CLASS ACTION COMPLAINT",
"Bioenvision, Inc. Says Securities Class Action Litigation Without Merit"
07/16/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Press release"
05/30/2007 8-K Material Modifications to Rights of Security Holders, Financial Statements and Exhibits
Docs: "AMENDMENT NO. 1 TO RIGHTS AGREEMENT THIS AMENDMENT NO. 1 TO RIGHTS AGREEMENT is made as of the 30th day of May, 2007, by and between BIOENVISION, INC., a Delaware corporation , and AMERICAN STOCK TRANSFER & TRUST COMPANY, a New York banking corporation . WHEREAS, the Company has entered into an Agreement and Plan of Merger , among the Company, Genzyme Corporation, a Massachusetts corporation , and Wichita Bio Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent , pursuant to which Purchaser will: make a tender offer to acquire all of the issued and outstanding shares of common stock of the Company, par value $0.001 per share , and all of the issued and outstanding shares of Series A Convertible Participating Preferred Stock of the Company, par value $0.001 per share ..."
05/29/2007 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Genzyme Corporation, a Massachusetts corporation, Wichita Bio Corporation, and Bioenvision, Inc., a Delaware corporation",
"Form of Tender and Voting Agreement, by and among Genzyme Corporation, Wichita Bio Corporation and certain stockholders of Bioenvision, Inc"
05/29/2007 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Genzyme Corporation to Acquire Bioenvision, Inc. ---------------------------------------------------------------------------- To Gain Exclusive, Worldwide Rights to Clofarabine"
05/25/2007 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Amendment to Co-Development Agreement, by and between the Company and Southern Research Institute"
05/09/2007 8-K Quarterly results
Docs: "Bioenvision Reports Third Quarter 2007 Financial Results"
05/04/2007 8-K Unregistered Sales of Equity Securities
04/26/2007 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Compromise Agreement by and between Bioenvision Limited and Dr. Andrew Saunders"
04/02/2007 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Placement Agency Agreement dated March 30, 2007, by and between Bioenvision, Inc. and J.P. Morgan Securities Inc",
"Opinion of Paul, Hastings, Janofsky & Walker LLP",
"Bioenvision Announces Registered Direct Offering of $30 Million in Common Stock -"
03/30/2007 8-K Financial Statements and Exhibits
Docs: "Consent of J.H. Cohn LLP, Independent Registered Public Accounting Firm",
"Consent of Deloitte & Touche LLP, Prior Independent Registered Public Accounting Firm",
"Consent of Grant Thornton LLP, Prior Independent Registered Public Accounting Firm"
02/13/2007 8-K Quarterly results
Docs: "Bioenvision Reports Second Quarter 2007 Financial Results; Evoltra® Sales Double Over Last Quarter - Bioenvision, Inc. today announced financial results for the second quarter ended December 31, 2006. Results and recent events include: Ø Bioenvision marks record quarterly revenue of $4.5 million as Evoltra ® sales doubled from the first quarter of 2007 Ø Bioenvision files with the EMeA for label extension of Evoltra in elderly AML Ø ASH conference spotlights pivotal filing data from study BIOV-121 Ø Bioenvision appoints new Chief Financial Officer Ø Bioenvision appoints General Manager for Bioenvision JapanCo. Ø Bioenvision out-licenses worldwide rights to its Oligon technology “We are very pleased with the impact our sales and marketing or..."
02/06/2007 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Entrustment Agreement by and between the Company and Yoshimaru Yamamoto",
"Bioenvision Appoints General Manager in Japan"
11/30/2006 8-K Appointed CFO
Docs: "Employment Agreement by and between the Company and James S. Scibetta",
"BIOENVISION APPOINTS JAMES S. SCIBETTA AS NEW CFO - Bioenvision, Inc. today announced the appointment James S. Scibetta to the post of Chief Financial Officer. Mr. Scibetta will begin his employment with Bioenvision in early December 2006. Mr. Scibetta, with 18 years of experience as a finance professional, will become the Company's new CFO. Mr. Scibetta was most recently Executive Vice President & CFO of Merrimack Pharmaceuticals, Inc. of Cambridge, Massachusetts, a biopharmaceutical company focused on discovery and development of novel therapies for autoimmune disease and cancer. Mr. Scibetta is a member of the board of directors and audit committee chairman of Labopharm Inc. , an international, specialty pharmaceutical company focused on improving existing drugs by incorporating its pro..."
11/13/2006 8-K Quarterly results
Docs: "Item 2.02. Results of Operations and Financial Condition.",
"BIOENVISION REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS"
10/11/2006 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "in the Private Securities Litigation Reform Act of"
09/18/2006 8-K Entry into a Material Definitive Agreement
05/18/2006 8-K Quarterly results
Docs: "BIOENVISION REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS NEW YORK, N.Y., May 15, 2006 - Bioenvision today announced financial results for the third quarter ended March 31, 2006. Highlights of the quarter include:"
04/19/2006 8-K Auditor change
04/06/2006 8-K Entry into a Material Definitive Agreement
02/23/2006 8-K Other Events, Financial Statements and Exhibits
Docs: "BIOENVISION'S CLOFARABINE RECEIVES A POSITIVE OPINION FROM THE EUROPEAN MEDICINES AGENCY"
02/17/2006 8-K Quarterly results
Docs: "BIOENVISION REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS"
02/10/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment to Employment Agreement by and between the Company and David P. Luci"
01/20/2006 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter of Deloitte & Touche LLP to the Securities and Exchange Commission"
11/28/2005 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Item 3.01 Notice of Delisting",
"Bioenvision, Inc. Receives Notice Regarding Continued Compliance with Nasdaq's Director Nomination Rules"
11/15/2005 8-K Quarterly results
Docs: "Item 2.02. Results of Operations and Financial Condition.",
"BIOENVISION REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS"
10/14/2005 8-K Quarterly results
Docs: "Item 2.02. Results of Operations and Financial Condition.",
"BIOENVISION REPORTS 2005 YEAR-END FINANCIAL RESULTS"
07/01/2005 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Item 2.02. Results of Operations and Financial Condition.",
"BIOENVISION REPORTS THIRD QUARTER FISCAL 2005 FINANCIAL RESULTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy